^
Association details:
| Biomarker: | PTEN expression |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer
Excerpt:
...Progression Free Survival (PFS), as Assessed by the Investigator`Time to First CNS Progression, Defined as the Time From Randomization Until the Date of Documented CNS Progression as the First Site of Relapse`Overall Survival`Number of Participants With Overall Response (OR), as Assessed by the Investigator`Number of Participants With Clinical Benefit (CB)`Duration of Response`Number of Participants With CNS Progression at Any Time`Number of Participants With Qualitative and Quantitative Toxicities`Number of Participants Expressing Glucocorticoid Receptor, Phosphatase and Tensin Homolog (PTEN), Phosphatidylinositide 3-kinase (PI3K)/AKT, Protein 53 (P53), Insulin-like Growth Factor-1 (IGF-1), and Genes Involved in Cell Cycle Regulation`Number of Participants With the Indicated Grade 3 or Grade 4 Adverse Events (AEs) Occurring in >=2% of Participants in Either Treatment Arm...
Trial ID:
Source:
Title:
Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study
Excerpt:
...Percentage of Participants With the Indicated Biomarker Expression - PTEN.`...
Trial ID:
Less C2 evidence
Source:
Title:
PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer
Excerpt:
Of the 17 patients who received trastuzumab plus paclitaxel, those who had PTEN-deficient tumours (− and 1+: IRS<7) had significantly lower complete and partial response rates to trastuzumab therapy than those with PTEN-positive tumors (2+ and 3+ or IRS⩾7; 12.50 vs 88.89%, P=0.00337) (Figure 9).
Secondary therapy:
paclitaxel
DOI:
10.1038/sj.bjc.6602926
